Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.

SG&A Expenses: A Decade of Strategic Growth in Biotech

__timestampMadrigal Pharmaceuticals, Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 20141574600010811000
Thursday, January 1, 20151339200033001000
Friday, January 1, 2016929000064936000
Sunday, January 1, 2017767200099909000
Monday, January 1, 201815293000127724000
Tuesday, January 1, 201922648000161524000
Wednesday, January 1, 202021864000182933000
Friday, January 1, 202137318000219982000
Saturday, January 1, 202248130000278139000
Sunday, January 1, 2023108146000309799000
Loading chart...

In pursuit of knowledge

Navigating SG&A Expenses: A Tale of Two Biotechs

In the competitive landscape of biotechnology, effective cost management is crucial. Madrigal Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Madrigal's Selling, General, and Administrative (SG&A) expenses surged by over 580%, peaking in 2023. Meanwhile, Ultragenyx's expenses grew by approximately 280% during the same period, reflecting its aggressive expansion strategy.

A Decade of Growth and Strategy

Madrigal's expenses remained relatively stable until 2020, after which they more than doubled, indicating a strategic shift or increased operational activities. Ultragenyx, on the other hand, consistently increased its SG&A spending, with a notable jump in 2015 and a steady rise thereafter. This trend suggests a focus on scaling operations and market presence.

Understanding these trends provides valuable insights into how these companies manage their growth and operational strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025